Biogen (BIIB) to Release Quarterly Earnings on Tuesday

Biogen (NASDAQ:BIIB - Get Free Report) will likely be releasing its earnings data before the market opens on Tuesday, February 11th. Analysts expect Biogen to post earnings of $3.43 per share and revenue of $2.42 billion for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Biogen Trading Up 2.1 %

Biogen stock traded up $3.04 during trading hours on Wednesday, reaching $145.53. The company had a trading volume of 1,173,200 shares, compared to its average volume of 1,265,540. The company has a 50-day moving average price of $150.16 and a 200 day moving average price of $177.18. Biogen has a 12-month low of $139.71 and a 12-month high of $246.44. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The firm has a market cap of $21.21 billion, a price-to-earnings ratio of 13.15, a P/E/G ratio of 1.66 and a beta of -0.08.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BIIB shares. Oppenheimer reduced their target price on Biogen from $270.00 to $255.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. Stifel Nicolaus downgraded Biogen from a "buy" rating to a "hold" rating and set a $175.00 target price on the stock. in a research note on Monday, December 16th. JPMorgan Chase & Co. cut their target price on shares of Biogen from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Monday, November 4th. StockNews.com cut shares of Biogen from a "strong-buy" rating to a "buy" rating in a research note on Saturday, December 28th. Finally, Barclays lowered their price target on shares of Biogen from $190.00 to $180.00 and set an "equal weight" rating on the stock in a report on Thursday, October 31st. Sixteen equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, Biogen currently has an average rating of "Hold" and an average target price of $228.80.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.